25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist. It has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion L1148. It was discovered in 2014 at the University of Copenhagen.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Hydrocodone | N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Magnesium sulfate | The therapeutic efficacy of N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Orphenadrine | N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Pramipexole | N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine may increase the sedative activities of Pramipexole. |
| Ropinirole | N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine may increase the sedative activities of Ropinirole. |
| Rotigotine | N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Sodium oxybate | N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Thalidomide | N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Dicoumarol | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Dicoumarol. |
| Phenindione | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Phenindione. |
| Warfarin | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Warfarin. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Coumarin. |
| (R)-warfarin | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Fluindione. |
| Clorindione | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Diphenadione. |
| Tioclomarol | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with (S)-Warfarin. |
| Mirtazapine | N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine may increase the serotonergic activities of Mirtazapine. |
| Ethanol | N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Duloxetine. |
| Paroxetine | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Nefazodone. |
| Zimelidine | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Seproxetine | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Seproxetine. |
| Levomilnacipran | The risk or severity of serotonin syndrome can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Levomilnacipran. |
| Indalpine | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Alaproclate. |
| Methylene blue | N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine may increase the serotonergic activities of Methylene blue. |
| Zopiclone | The risk or severity of adverse effects can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Tryptophan | The risk or severity of CNS depression can be increased when Tryptophan is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Lorazepam | The risk or severity of CNS depression can be increased when Lorazepam is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Reserpine | The risk or severity of CNS depression can be increased when Reserpine is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Temazepam | The risk or severity of CNS depression can be increased when Temazepam is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Reboxetine | The risk or severity of CNS depression can be increased when Reboxetine is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Butalbital | The risk or severity of CNS depression can be increased when Butalbital is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Methysergide | The risk or severity of CNS depression can be increased when Methysergide is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Cabergoline | The risk or severity of CNS depression can be increased when Cabergoline is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Phenytoin | The risk or severity of CNS depression can be increased when Phenytoin is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Topiramate | The risk or severity of CNS depression can be increased when Topiramate is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Clemastine | The risk or severity of CNS depression can be increased when Clemastine is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Venlafaxine | The risk or severity of serotonin syndrome can be increased when N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine is combined with Venlafaxine. |
| Etomidate | The risk or severity of CNS depression can be increased when Etomidate is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Morphine | The risk or severity of CNS depression can be increased when Morphine is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Talbutal | The risk or severity of CNS depression can be increased when Talbutal is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Pentobarbital | The risk or severity of CNS depression can be increased when Pentobarbital is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Valproic acid | The risk or severity of CNS depression can be increased when Valproic acid is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Zolmitriptan | The risk or severity of CNS depression can be increased when Zolmitriptan is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Codeine | The risk or severity of CNS depression can be increased when Codeine is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Dihydroergotamine | The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Amitriptyline | The risk or severity of CNS depression can be increased when Amitriptyline is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Tolcapone | The risk or severity of CNS depression can be increased when Tolcapone is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Hydromorphone | The risk or severity of CNS depression can be increased when Hydromorphone is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Olanzapine | The risk or severity of CNS depression can be increased when Olanzapine is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Cetirizine | The risk or severity of CNS depression can be increased when Cetirizine is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Protriptyline | The risk or severity of CNS depression can be increased when Protriptyline is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Trimethadione | The risk or severity of CNS depression can be increased when Trimethadione is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Clobazam | The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Chlorzoxazone | The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Clozapine | The risk or severity of CNS depression can be increased when Clozapine is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |
| Meprobamate | The risk or severity of CNS depression can be increased when Meprobamate is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. |